Johnson L. Thistle – 1 January 1987 – The efficacy and safety of mono‐octanoin, a cholesterol solvent for the direct dissolution of stones in the biliary tract, was assessed by collating case reports on 343 patients provided by 222 physicians who used the material between 1977 and 1983. Most patients had previously undergone cholecystectomy, with common duct exploration, the majority within the preceding six weeks. In most, sphincterotomy was impossible or if carried out, had not induced stone passage.

M. Bernardi, F. Trevisani, Asghar Rastegar – 1 January 1987

Michiyasu Fujita, David C. Spray, Haing Choi, Juan C. Saez, Tohru Watanabe, Larry C. Rosenberg, Elliott L. Hertzberg, Lola M. Reid – 1 January 1987 – Normal rat hepatocytes maintained on tissue culture plastic and in serum‐supplemented medium lose their gap junctions within 12 hr and expression of their tissue‐specific functions within 24 to 72 hr. The gap junctions are lost via internalization and degradation, and the differentiated functions due to loss of synthesis and to rapid degradation of tissue‐specific mRNAs.

David H. Alpers – 1 January 1987

1 January 1987

Vlado Simko, Shoukry Michael, Robert E. Kelley – 1 January 1987 – Bile acids, in a random sample of urine, discriminated normal controls from liver disease, with a probability similar to fasting plasma bile acids (p < 0.01 and p < 0.001, depending on the analytical technique). A high degree of correlation between urinary and plasma bile acids (up to r = 0.93) was achieved only when the urine flow was corrected by using a urinary bile acids/creatinine ratio but not with urinary bile acids as simple volume concentration.

R. Adron Harris, Francis R. Simon – 1 January 1987

Charles L. Mendenhall, Harold O. Conn – 1 January 1987

Thomas D. Boyer – 1 January 1987

Allan R. Shatzman, Martin Rosenberg – 1 January 1987 – There are numerous proteins of biological interest which cannot be obtained from natural sources in quantities sufficient for detailed biochemical and physical analysis. The limited bioavailability of these molecules has made it impossible to consider their potential utilization as either pharmacological agents and/or targets. One solution to this problem has been the development of recombinant vector systems which are designed to achieve efficient expression of cloned genes in a variety of biological systems.